Dierks Jeffrey 4
4 · Harmony Biosciences Holdings, Inc. · Filed Jan 21, 2025
Insider Transaction Report
Form 4
Dierks Jeffrey
CHIEF COMMERCIAL OFFICER
Transactions
- Sale
Common Stock
2025-01-21$40.00/sh−1,123$44,920→ 0 total - Exercise/Conversion
Stock Option
2025-01-16−29,475→ 6,738 totalExercise: $33.44Exp: 2031-06-01→ Common Stock (29,475 underlying) - Exercise/Conversion
Common Stock
2025-01-16$33.44/sh+29,475$985,644→ 29,475 total - Sale
Common Stock
2025-01-16$37.41/sh−29,475$1,102,795→ 0 total - Exercise/Conversion
Common Stock
2025-01-21$33.44/sh+1,123$37,553→ 1,123 total - Exercise/Conversion
Stock Option
2025-01-21−1,123→ 5,615 totalExercise: $33.44Exp: 2031-06-01→ Common Stock (1,123 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.98. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The stock option shall vest with respect to 50% of the underlying shares on June 1, 2023 and with respect to the remaining shares, in twenty-four equal monthly installments beginning on July 1, 2023.